abstract: @entity565 is a complex inflammatory disease involving the critical actions of several important cytokines. Epidemiological data show that @entity28 could increase the risk of @entity565 , and insulin resistance, or @entity209 are an important risk factor for @entity28 @entity565 . Some studies identified that upstream of the transcription start site within the @entity310 gene promoter region-308 polymorphism was associated insulin resistance or @entity209 , while this site was closely related to @entity565 . But no research was performed to evaluate the influence of @entity310 @entity15646 polymorphism on @entity209 in @entity748 @entity1 . Here, we recruited 248 @entity748 @entity1 , who were separated into @entity565 with Mets/ @entity565 without Mets groups and 226 matched healthy controls from Hebei Province to evaluate the influence of @entity310 @entity15646 polymorphism on @entity209 in @entity748 @entity1 . Single nucleotide polymorphism of @entity310 -308 locus was genotyped using PCR-RFLP. Some biochemical variables were also determined. Our result showed that the genotypic and allelic frequency of @entity40610 did not show significant difference between @entity748 @entity1 and normal controls. However, the frequency of A allele was signi   cantly higher in @entity565 group with Mets (22.36%) than in controls (15.71%) (P = 0.02; OR = 0.647; 95% CI = 0.447-0.936). After analyzing the relationship between biochemical features of @entity1 and genotype of @entity310 @entity15646 , we found levels of LDL @entity165 , @entity310 and insulin, and HOMA-IR were significantly higher in the @entity748 @entity1 carrying the GA and AA genotypes than in the carriers of GG genotype of @entity40610 (P = 0.029, P = 0.022, P = 0.043, respectively). Thus, our data suggested that @entity310 @entity15646 variation was related to metabolic phenotype in @entity565 @entity1 . Furthermore, we first identified @entity310 -308 A allele was the risk factor for @entity748 @entity1 with Mets in Hebei population, China.

title: Genetic polymorphisms of the @entity310 @entity15646 are associated with @entity209 in @entity748 XXXX from Hebei province, China.

answer: @entity1 :: (9606,Species) :: ['patients']


abstract: AIM: To determine whether fluoroscope time is a good predictor of @entity1 radiation exposure during endoscopic retrograde cholangiopancreatography. METHODS: This is a prospective observational study of consecutive @entity1 undergoing endoscopic retrograde cholangiopancreatography in a tertiary care setting. Data related to radiation exposure were collected. The following measures were obtained: @entity1054 ( @entity1054 ), dose area product (DAP) and dose at reference point (DOSERP). Coefficients of determination were calculated to analyze the correlation between @entity1054 , DAP and DOSRP. Agreement between @entity1054 and DAP/DOSRP was assessed using Bland Altman plots. RESULTS: Four hundred sixty-three data sets were obtained. @entity1054 average was 7.3 min. Fluoroscopy related radiation accounted for 86% of the total DAP while acquisition films related radiation accounted for 14% of the DAP. For any given @entity1054 there are wide ranges of DAP and DOSERP and the variability in both increases as fluoroscopy time increases. The coefficient of determination (R(2)) on the non transformed data for DAP and DOSERP versus @entity1054 were respectively 0.416 and 0.554. While fluoroscopy use was the largest contributor to @entity1 radiation exposure during endoscopic retrograde cholangiography (ERCP), there is a wide variability in DAP and DOSERP that is not accounted for by @entity1054 . DAP and DOSERP increase in variability as @entity1054 increases. This translates into poor accuracy of @entity1054 in predicting DAP and DOSERP at higher radiation doses. CONCLUSION: DAP and DOSERP in addition to @entity1054 should be adopted as new ERCP quality measures to estimate @entity1 radiation exposure.

title: Measures of XXXX radiation exposure during endoscopic retrograde cholangiography: beyond fluoroscopy time.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity1054 :: ('MESH:D000377', 'Disease') :: ['Fluoroscopy time', 'FT']

answer: @entity1 :: (9606,Species) :: ['patient']


abstract: The lethal effects of combinations of @entity632 (ADR) and either @entity1862 (HU) or @entity9864 ( @entity2592 ) were studied in relation to drug-scheduling interval in @entity19 cells grown in vitro. @entity734 was determined by cell cloning in soft agar. Serial kinetic changes induced by a priming dose of HU or @entity2592 were monitored by flow cytometry and related to schedule-dependent cell killing by ADR. All drug exposures were for 1 hr. When ADR was given together with either HU or @entity2592 , cell log kill was additive. However, when ADR was given after exposure to either HU or @entity2592 , cell killing was increased up to 200- to 500-fold, respectively. Maximum schedule-dependent synergism was observed at a drug-scheduling interval of 2 hr; schedule-dependent synergism decreased as the interval between drugs was increased beyond 2 hr. Schedule-dependent synergism was not observed when the same drug combinations were given in reversed order. Drug-induced changes in the DNA histogram were not seen until 5 hr after HU exposure and 8 hr after @entity2592 exposure. Thus, the schedule-dependent synergism between ADR and either HU or @entity2592 cannot be explained by cell cycle blockade with synchronization of cells in S phase.

title: Schedule-dependent synergism of combinations of XXXX with @entity632 and @entity9864 with @entity632 .

entities_list: @entity632 :: ('MESH:D004317', 'Chemical') :: ['adriamycin']

entities_list: @entity1862 :: ('MESH:D006918', 'Chemical') :: ['hydroxyurea']

entities_list: @entity9864 :: ('CHEBI:28680', 'Chemical') :: ['1-beta-d-arabinofuranosylcytosine']

entities_list: @entity734 :: ('MESH:D019966', 'Disease') :: ['Drug lethality']

answer: @entity1862 :: (MESH:D006918,Chemical) :: ['hydroxyurea']


abstract: The lethal effects of combinations of @entity632 (ADR) and either @entity1862 (HU) or @entity9864 ( @entity2592 ) were studied in relation to drug-scheduling interval in @entity19 cells grown in vitro. @entity734 was determined by cell cloning in soft agar. Serial kinetic changes induced by a priming dose of HU or @entity2592 were monitored by flow cytometry and related to schedule-dependent cell killing by ADR. All drug exposures were for 1 hr. When ADR was given together with either HU or @entity2592 , cell log kill was additive. However, when ADR was given after exposure to either HU or @entity2592 , cell killing was increased up to 200- to 500-fold, respectively. Maximum schedule-dependent synergism was observed at a drug-scheduling interval of 2 hr; schedule-dependent synergism decreased as the interval between drugs was increased beyond 2 hr. Schedule-dependent synergism was not observed when the same drug combinations were given in reversed order. Drug-induced changes in the DNA histogram were not seen until 5 hr after HU exposure and 8 hr after @entity2592 exposure. Thus, the schedule-dependent synergism between ADR and either HU or @entity2592 cannot be explained by cell cycle blockade with synchronization of cells in S phase.

title: Schedule-dependent synergism of combinations of @entity1862 with XXXX and @entity9864 with @entity632 .

answer: @entity632 :: (MESH:D004317,Chemical) :: ['adriamycin']


abstract: The lethal effects of combinations of @entity632 (ADR) and either @entity1862 (HU) or @entity9864 ( @entity2592 ) were studied in relation to drug-scheduling interval in @entity19 cells grown in vitro. @entity734 was determined by cell cloning in soft agar. Serial kinetic changes induced by a priming dose of HU or @entity2592 were monitored by flow cytometry and related to schedule-dependent cell killing by ADR. All drug exposures were for 1 hr. When ADR was given together with either HU or @entity2592 , cell log kill was additive. However, when ADR was given after exposure to either HU or @entity2592 , cell killing was increased up to 200- to 500-fold, respectively. Maximum schedule-dependent synergism was observed at a drug-scheduling interval of 2 hr; schedule-dependent synergism decreased as the interval between drugs was increased beyond 2 hr. Schedule-dependent synergism was not observed when the same drug combinations were given in reversed order. Drug-induced changes in the DNA histogram were not seen until 5 hr after HU exposure and 8 hr after @entity2592 exposure. Thus, the schedule-dependent synergism between ADR and either HU or @entity2592 cannot be explained by cell cycle blockade with synchronization of cells in S phase.

title: Schedule-dependent synergism of combinations of @entity1862 with @entity632 and @entity9864 with XXXX .

answer: @entity632 :: (MESH:D004317,Chemical) :: ['adriamycin']


abstract: The lethal effects of combinations of @entity632 (ADR) and either @entity1862 (HU) or @entity9864 ( @entity2592 ) were studied in relation to drug-scheduling interval in @entity19 cells grown in vitro. @entity734 was determined by cell cloning in soft agar. Serial kinetic changes induced by a priming dose of HU or @entity2592 were monitored by flow cytometry and related to schedule-dependent cell killing by ADR. All drug exposures were for 1 hr. When ADR was given together with either HU or @entity2592 , cell log kill was additive. However, when ADR was given after exposure to either HU or @entity2592 , cell killing was increased up to 200- to 500-fold, respectively. Maximum schedule-dependent synergism was observed at a drug-scheduling interval of 2 hr; schedule-dependent synergism decreased as the interval between drugs was increased beyond 2 hr. Schedule-dependent synergism was not observed when the same drug combinations were given in reversed order. Drug-induced changes in the DNA histogram were not seen until 5 hr after HU exposure and 8 hr after @entity2592 exposure. Thus, the schedule-dependent synergism between ADR and either HU or @entity2592 cannot be explained by cell cycle blockade with synchronization of cells in S phase.

title: Schedule-dependent synergism of combinations of @entity1862 with @entity632 and XXXX with @entity632 .

answer: @entity9864 :: (CHEBI:28680,Chemical) :: ['1-beta-D-arabinofuranosylcytosine']


abstract: @entity9643 does not occur only in the South West Province of Cameroon. Four foci exist in the country. They are the well known focus in the Mount Kupe area, the Mbam focus, the Nyong focus and the Ntem focus. All of them are located in the rainforest within the distribution area of Potadoma. This disease, characterized by the presence of eggs in sputum and feces, has often been confused with @entity378 . In the villages where @entity9643 is diagnosed by means of parasitological techniques circulating antibodies, revealed with a P. westermani antigen (ELISA), are often found in blood specimens taken from inhabitants. Teen agers suffer the most from the disease and females more often than males. @entity1 and @entity1 are traditionally concerned with crabs fishing and they eat them after partly raw. Crabs of the genus Sudanautes contain the infective metacercariae. @entity9643 is enzootic and the civet cat V. civetta seems to be the main natural definitive host in Cameroon. @entity66868 given orally in a single dose of 2 mg/kg body weight showed a 100% cure rate. Side reactions are mild and transient.

title: [Epidemiologic and clinical study of paragonimosis in Cameroon. Results of XXXX treatment].

entities_list: @entity1 :: ('9606', 'Species') :: ['children', 'Women']

entities_list: @entity66868 :: ('MESH:D009533', 'Chemical') :: ['Niclofolan']

entities_list: @entity378 :: ('MESH:D014376', 'Disease') :: ['tuberculosis']

entities_list: @entity9643 :: ('MESH:D010237', 'Disease') :: ['paragonimiasis', 'Paragonimiasis']

answer: @entity66868 :: (MESH:D009533,Chemical) :: ['niclofolan']


abstract: OBJECTIVE: The purpose of this work was to analyze the relationships between the expression status of Lysosomal-associated protein transmembrane-4 beta 35 ( @entity22489 -35) in cancerous tissues and clinicopathological characteristics and prognosis of the @entity1 with @entity356 ( @entity356 ). METHODS: The @entity356 samples from 157 @entity1 in a discovery cohort and 148 @entity1 in a testing cohort with follow-up data were used to validate the feasibility of expression of @entity22489 -35 protein in predicting @entity356 prognosis. Immunohistochemical staining was used to determine the expression of @entity22489 -35 protein in precancerous @entity356 . The correlation between the expression of @entity22489 -35 and clinicopathologic characteristics of @entity1 with @entity356 was analyzed using chi-square test. Univariate and multivariate analyses were performed to determine the association between @entity22489 -35 expression and prognosis. RESULTS: @entity22489 -35 expression was increased steadily in sequential stages of precancerous @entity1819 . Positive @entity22489 -35 expression was more frequently detected in @entity1 with distant @entity3 (P = 0.023) and III+IV TNM stages (P = 0.042) in the discovery cohort. Kaplan-Meier survival curves and univariate analysis showed that expression of @entity22489 -35 had a significant impact on overall survival of @entity1 with @entity356 in discovery cohort (P<0.001) and testing cohort (P = 0.001). @entity22489 -35 expression was an independent prognostic indicator for the overall survival of @entity1 with @entity356 in both cohorts. CONCLUSIONS: The present research demonstrated that @entity22489 -35 over-expression was an independent factor in @entity356 prognosis. @entity22489 gene may be a useful target of interventions slowing the progression of precancerous @entity1819 and a new therapy method to improve the prognosis of @entity356 .

title: Lysosomal-associated protein transmembrane 4 Beta-35 overexpression is a novel independent prognostic marker for XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity1819 :: ('MESH:D013272', 'Disease') :: ['gastric lesions']

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['metastasis']

entities_list: @entity356 :: ('MESH:D013274', 'Disease') :: ['gastric lesions and gastric carcinomas', 'gastric carcinoma', 'GC']

answer: @entity356 :: (MESH:D013274,Disease) :: ['gastric carcinoma']


abstract: Prazosin kinetics were studied after single doses (intravenous and oral, 0.5 mg) and after increasing multiple doses (0.5 to 5 mg three times daily) in eight @entity1 with @entity101 . After intravenous administration the kinetics could be described by a linear two-compartment open model. Terminal half-life ( @entity5893 ) was about 3 hr and apparent volume of distribution ( @entity12095 ) about 0.6 l/kg. After oral doses bioavailability ranged between 55% and 82%. Since total plasma clearance was low (0.14 l/kg x hr) incomplete bioavailability was the result of incomplete absorption rather than of first-pass liver metabolism. The estimated extraction ratio was about 14%. Renal clearance was negligible; only 1% to 2% of the dose was recovered unchanged in urine. Binding to plasma proteins to both albumin and alpha 1-acid glycoprotein was substantial (97%), with albumin being most important. Increasing multiple doses showed that @entity3159 followed first-order kinetics with a linear correlation between dose and steady-state plasma concentration (P less than 0.001). There were substantial variations in plasma concentrations between @entity1 and there were also day-to-day variations in concentration within the same @entity1 .

title: Prazosin kinetics in XXXX .

entities_list: @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension']

entities_list: @entity3159 :: ('MESH:D011224', 'Chemical') :: ['prazosin']

answer: @entity101 :: (MESH:D006973,Disease) :: ['hypertension']


abstract: UNASSIGNED: OBJECTIVE The authors undertook this study to validate the feasibility and safety of stereotactic radiofrequency thermocoagulation (SRT) for the surgical treatment of @entity10128 ( @entity10128 ). METHODS Of the 109 @entity1 who underwent SRT for @entity10128 ( @entity10128 ) at the authors' institution between 1997 and 2013, 16 @entity1 (9 female, 7 male) had giant HHs (maximum diameter >=  30 mm). The clinical records of these 16 @entity1 were retrospectively reviewed. RESULTS The @entity1 ' age at first SRT ranged from 1 to 22 years (median 5 years). The maximum diameter of their HHs was 30-80 mm (mean 38.5 mm). Eleven HHs had bilateral attachments to the hypothalamus. All @entity1 had @entity410 ( @entity410 ), and 12 had types of @entity410 other than @entity410 . Some of these @entity1 also had @entity1032 (n = 10, 62.5%), @entity146 (n = 8, 50.0%), and precocious puberty (n = 11, 68.8%). A total of 22 SRT procedures were performed; 5 @entity1 underwent repeat SRT procedures. There was no mortality or permanent morbidity. After 17 of the 22 procedures, the @entity1 experienced transient complications, including high fever (n = 7), @entity7298 (n = 3), @entity2753 (n = 6), disturbance of consciousness (n = 1), @entity1283 (n = 1), and epidural @entity1410 (n = 1). Thirteen @entity1 (81.3%) achieved freedom from @entity410 after the final SRT procedure during a follow-up period ranging from 6 to 60 months (mean 23 months). Twelve @entity1 had nongelastic @entity410 in addition to @entity410 , and 7 (58.3%) of these 12 @entity1 experienced freedom from their nongelastic @entity410 . CONCLUSIONS SRT provided minimal invasiveness and excellent @entity410 outcomes even in @entity1 with giant HHs. Repeat SRT is safe for residual @entity410 . SRT is a feasible single surgical strategy for @entity10128 regardless of the @entity5 's size or shape.

title: Stereotactic radiofrequency thermocoagulation for XXXX .

entities_list: @entity1032 :: ('MESH:D008607', 'Disease') :: ['mental retardation']

entities_list: @entity410 :: ('MESH:D012640', 'Disease') :: ['gelastic seizures', 'seizure', 'seizures', 'GS']

entities_list: @entity146 :: ('MESH:D001523', 'Disease') :: ['behavioral disorders']

entities_list: @entity7298 :: ('MESH:D006963', 'Disease') :: ['hyperphagia']

entities_list: @entity1283 :: ('MESH:D006332', 'Disease') :: ['cyst enlargement']

entities_list: @entity10128 :: ('MESH:C537158', 'Disease') :: ['giant hypothalamic hamartoma', 'HH', 'hypothalamic hamartoma']

entities_list: @entity2753 :: ('MESH:D007010', 'Disease') :: ['hyponatremia']

answer: @entity10128 :: (MESH:C537158,Disease) :: ['giant hypothalamic hamartoma']


abstract: PURPOSE OF REVIEW: Transcatheter @entity886 (TAVI) is the recommended treatment for most @entity1 with @entity472 at high surgical risk. However, TAVI may be clinically futile for @entity1 who have multiple comorbidities and excessive frailty. This group benefits from transition to palliative care to maximize quality of life, improve symptoms, and ensure continuity of health services. We discuss the clinical determination of utility and futility, explore the current evidence guiding the integration of palliative care in procedure-focused cardiac programs, and outline recommendations for TAVI programs. RECENT FINDINGS: The determination of futility of treatment in elderly @entity1 with @entity472 is challenging. There is a paucity of research available to guide best practices when TAVI is not an option. Opportunities exist to build on the evidence gained in the management of end of life and @entity712 . TAVI programs and primary care providers can facilitate improved communication and processes of care to provide decision support and transition to palliative care. SUMMARY: The increased availability of transcatheter options for the management of @entity340 will increase the assessment of @entity1 with life-limiting conditions for whom treatment may not be an option. It is pivotal to bridge cardiac innovation and palliation to optimize @entity1 outcomes.

title: Transition to palliative care when transcatheter XXXX is not an option: opportunities and recommendations.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient', 'people']

entities_list: @entity340 :: ('MESH:D006349', 'Disease') :: ['valvular heart disease']

entities_list: @entity712 :: ('MESH:D006333', 'Disease') :: ['heart failure']

entities_list: @entity886 :: ('MESH:C563178', 'Disease') :: ['aortic valve implantation']

entities_list: @entity472 :: ('MESH:D001024', 'Disease') :: ['symptomatic aortic stenosis', 'aortic stenosis']

answer: @entity886 :: (MESH:C563178,Disease) :: ['aortic valve implantation']


abstract: Importance: @entity6313 is the most common disease of the nail in adults. International guidelines urge health care professionals to perform confirmatory diagnostic testing before initiating systemic therapy. This approach was determined to be cost-effective in studies from the late 1990s but has not been evaluated more recently. The effect of testing on the costs of @entity36018 , 10%, topical solution treatment is unknown. Objective: To evaluate the cost and potential harm associated with 3 approaches to @entity6313 evaluation before treatment with oral @entity8974 or @entity36018 , 10%. Design, Setting, and @entity1 : A decision analysis that compared the costs of 3 @entity6313 management algorithms based on recently published data of test statistics, disease prevalence, and relevant costs: (1) empirical therapy without confirmatory testing, (2) pretreatment confirmatory testing with @entity4014 ( @entity3071 ) stain followed by periodic acid-Schiff (PAS) evaluation if @entity3071 testing is negative, and (3) pretreatment testing with PAS. There was no direct @entity1 evaluation. Selection of included studies was based on outcome variables and the quality of study design. The study was conducted from April 1, 2014, to September 1, 2015. Main Outcomes and Measures: Primary outcomes included direct cost of @entity6313 testing and therapy and cost to avoid harm when treating @entity1 with oral @entity8974 . Results: At a disease prevalence of 75%, per- @entity1 cost savings of empirical @entity8974 therapy without confirmatory testing was  47 compared with the @entity3071 screening model and  135 compared with PAS testing. The cost of testing necessary to prevent a single case of clinically relevant liver toxic effects related to @entity8974 at a prevalence of 75% was between  18.2 million and  43.7 million for @entity3071 screening and between  37.6 million and  90.2 million for PAS testing. At a prevalence of 75%, @entity3071 screening and PAS testing before treatment with @entity36018 , 10%, saved  272 and  406 per @entity1 per nail, respectively. Conclusions and Relevance: These results show that empirical treatment with @entity8974 for @entity1 with suspected @entity6313 is more cost-effective than confirmatory testing across all prevalence of disease, with minimal effect on @entity1 safety. In contrast, confirmatory testing before treatment with @entity36018 , 10%, is associated with reduced costs. Blanket recommendations for confirmatory testing before systemic therapy should be reconsidered and replaced with recommendations tailored to specific therapies.

title: Cost-effectiveness of Confirmatory Testing Before Treatment of XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient', 'Participants']

entities_list: @entity8974 :: ('MESH:C041359', 'Chemical') :: ['terbinafine']

entities_list: @entity4014 :: ('MESH:C029943', 'Chemical') :: ['potassium hydroxide']

entities_list: @entity36018 :: ('MESH:C431707', 'Chemical') :: ['efinaconazole']

entities_list: @entity6313 :: ('MESH:D014009', 'Disease') :: ['Onychomycosis', 'onychomycosis']

answer: @entity6313 :: (MESH:D014009,Disease) :: ['Onychomycosis']


abstract: BACKGROUND/OBJECTIVES: The purpose of this observational study was to provide an impression of the outcomes of prehospital thrombolysis in combination with an active coronary angioplasty intervention (PCI) strategy for acute ST-elevation @entity583 . METHODS: In a group of 151 consecutive @entity1 the following parameters were measured: time delay, percentage of reperfusion, reocclusion, @entity64 , death, need for PCI and the number of protocol violations. RESULTS: The diagnosis by the ambulance paramedics was made in 8  6 minutes, followed by thrombolysis in 13  7 minutes (median  SD). In 2% (3) of the @entity1 the thrombolytic agent was erroneously administered without complications. The elapsed time from onset of symptoms to treatment was a median of 112  77 minutes. Five percent (7) of the @entity1 died in the first 30 days and 2% (3) suffered an @entity1779 . Reperfusion was documented in 76% (112) of the @entity1 , from which 18% (20) reoccluded in the following 24 hours. In @entity1 where reperfusion was not established or reocclusion occurred, @entity1 underwent rescue/facilitated PCI: in total 37% (55 @entity1 ). After three months 9% (13) of the @entity1 had severly impaired (EF <40%) left ventricular function. CONCLUSION: In our region, we successfully implemented the prehospital thrombolysis system achieving a competitive call-to-needle time and reperfusion rate. The percentage of @entity1 who violated the protocol, suffered an @entity1779 , died and/or had severely impaired left ventricular function was acceptable.

title: Safety and feasibility of prehospital thrombolysis in combination with active rescue PCI strategy for acute ST-elevation XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity583 :: ('MESH:D009203', 'Disease') :: ['myocardial infarction']

entities_list: @entity1779 :: ('MESH:D002543', 'Disease') :: ['intracerebral haemorrhage']

answer: @entity583 :: (MESH:D009203,Disease) :: ['myocardial infarction']


abstract: BACKGROUND: @entity299 , although benign, may produce symptoms related to @entity943 or mechanical obstruction. Surgical excision is the therapy of choice for symptomatic @entity4618 in infancy. @entity1 AND METHODS: Two @entity1 with @entity4618 producing symptoms underwent radiofrequency catheter ablation of the @entity5 . In @entity1 1 the diagnosis of multiple @entity4618 associated with recurrent @entity4710 was made in utero. After birth, several antiarrhythmic agents were administered, without successful suppression of the @entity591 . At seven months of age, the @entity1 had one large @entity5 on the left atrial aspect of the anterior mitral valve leaflet with associated @entity3155 and re-entrant supraventricular @entity591 suggestive of a left-sided pathway. Catheter ablation of the accessory pathway was performed via a retrograde femoral arterial approach, targeting the earliest site of ventricular activation. @entity1 2 presented as a neonate with multiple @entity4618 , one of which, measuring 15 mm * 15 mm, was producing severe mitral @entity340 resulting in symptoms of @entity712 due to a large left-to-right shunt at atrial level and persistent @entity120 . Via the femoral vein, a 5F ablation catheter was advanced across the @entity955 , and the @entity5 directly ablated. RESULTS: Echocardiography performed 24 hours later demonstrated alteration in @entity5 morphology, with the development of a large central echolucent area, followed by progressive @entity5 shrinkage in both @entity1 . @entity1 1 was discharged at 24 hours, and @entity1 2 at seven days post-ablation, without symptoms. Follow-up at four weeks confirmed further @entity5 shrinkage. CONCLUSION: Transcatheter @entity5 ablation may be beneficial in selected @entity1 and @entity1 .

title: XXXX producing symptoms in infancy: the role of radiofrequency catheter ablation.

entities_list: @entity1 :: ('9606', 'Species') :: ['children', 'patient', 'infants', 'PATIENTS', 'Patient', 'infant']

entities_list: @entity3155 :: ('MESH:D011226', 'Disease') :: ['pre-excitation']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['residual tumour', 'tumour']

entities_list: @entity120 :: ('MESH:D006976', 'Disease') :: ['pulmonary hypertension']

entities_list: @entity591 :: ('MESH:D013610', 'Disease') :: ['tachyarrhythmia']

entities_list: @entity4618 :: ('MESH:D012207', 'Disease') :: ['intracardiac rhabdomyomas', 'rhabdomyomas']

entities_list: @entity955 :: ('MESH:D001281', 'Disease') :: ['atrial septum']

entities_list: @entity299 :: ('MESH:D006331', 'Disease') :: ['Cardiac rhabdomyomas']

entities_list: @entity4710 :: ('MESH:D013617', 'Disease') :: ['supraventricular tachyarrhythmias and foetal hydrops']

entities_list: @entity340 :: ('MESH:D006349', 'Disease') :: ['valve inflow obstruction']

entities_list: @entity943 :: ('MESH:D001145', 'Disease') :: ['arrhythmia']

answer: @entity4618 :: (MESH:D012207,Disease) :: ['Intracardiac rhabdomyomas']


abstract: UNASSIGNED: In the classical form of a1-antitrypsin deficiency (ATD), aberrant intracellular accumulation of misfolded mutant a1-antitrypsin Z (ATZ) in hepatocytes causes @entity99 by a gain-of-function, "proteotoxic" mechanism. Whereas some ATD @entity1 develop @entity409 ( @entity409 ) that necessitates liver transplantation, others with the same @entity74 completely escape this clinical phenotype. We investigated whether induced pluripotent stem cells (iPSCs) from ATD individuals with or without @entity409 could model these personalized variations in @entity99 phenotypes. @entity1 -specific iPSCs were generated from ATD @entity1 and a control and differentiated into hepatocyte-like cells (iHeps) having many characteristics of hepatocytes. Pulse-chase and endoglycosidase H analysis demonstrate that the iHeps recapitulate the abnormal accumulation and processing of the ATZ molecule, compared to the wild-type AT molecule. Measurements of the fate of intracellular ATZ show a marked delay in the rate of ATZ degradation in iHeps from @entity409 @entity1 , compared to those from no @entity409 @entity1 . Transmission electron microscopy showed dilated rough endoplasmic reticulum in iHeps from all individuals with ATD, not in controls, but globular inclusions that are partially covered with ribosomes were observed only in iHeps from individuals with @entity409 . CONCLUSION: These results provide definitive validation that iHeps model the individual disease phenotypes of ATD @entity1 with more rapid degradation of misfolded ATZ and lack of globular inclusions in cells from @entity1 who have escaped @entity409 . The results support the concept that "proteostasis" mechanisms, such as intracellular degradation pathways, play a role in observed variations in clinical phenotype and show that iPSCs can potentially be used to facilitate predictions of disease susceptibility for more precise and timely application of therapeutic strategies. (Hepatology 2015).

title: Induced pluripotent stem cells model personalized variations in XXXX resulting from a1-antitrypsin deficiency.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'Patient']

entities_list: @entity74 :: ('MESH:D030342', 'Disease') :: ['genetic defect']

entities_list: @entity99 :: ('MESH:D056486', 'Disease') :: ['hepatic damage', 'hepatic disease']

entities_list: @entity409 :: ('MESH:D008107', 'Disease') :: ['severe liver disease', 'SLD', 'liver disease']

answer: @entity409 :: (MESH:D008107,Disease) :: ['liver disease']


abstract: BACKGROUND: @entity1358 is a @entity5 with a relatively good prognosis. The incidence of all @entity1358 is approximately 9/100,000 @entity1 . There are nearly 15,000 newly diagnosed @entity1 every year ( @entity1 twice as often as @entity1 ). TREND: In the last decade, a trend away from radical open resection towards nephron-sparing approaches has been observed. Currently, partial nephrectomy is the surgical gold standard for the treatment of small @entity703 . However, excellent clinical results are obtained using percutaneous radiofrequency ablation (RFA): low complication rates and preservation of the renal function. RESULTS: Primary and secondary technical success rates are 69-100% and 90-100%, respectively. In large series, major complication rates of RFA of 0-14% are reported. A relevant deterioration of renal function after RFA is very rare. The 5-year local recurrence-free survival rates, @entity3 -free survival rates, @entity5 -specific survival rates, and overall survival rates are 88-93, 95-100, 98-100, and 58.3-85%, respectively. In this context, the lack of appropriate long-term data is often cited as a limitation. CONCLUSION: Different meta-analyses come to the conclusion that in case of adequate @entity5 and @entity1 selection RFA shows oncologic results comparable with surgical resection. Accepted indications for RFA are T1  @entity703 in @entity1 with advanced age, significant comorbidities, reduced renal function, single kidney, and/or no wish for operation. Predictors for the success include @entity5 size and location as well as operator experience. To define the real efficacy of RFA in the treatment of @entity703 , randomized controlled clinical long-term studies are indicated.

title: [Percutaneous radiofrequency ablation of XXXX : Update 2015].

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'patients', 'patient', 'persons', 'men']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'cancer', 'malignancy']

entities_list: @entity1358 :: ('MESH:D002292', 'Disease') :: ['renal cell carcinomas', 'Stage I renal cell carcinoma']

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['metastasis']

entities_list: @entity703 :: ('MESH:D007680', 'Disease') :: ['renal tumors']

answer: @entity703 :: (MESH:D007680,Disease) :: ['renal tumors']


abstract: In order to ascertain the therapeutic effects of @entity3398 ( @entity5443 ), a new semisynthetic @entity12277 antibiotic, it was administered to pediatric @entity1 with several infections. There were 8 @entity1 with @entity1576 ( @entity1576 ), 3 with @entity293 ( @entity293 ), 2 with @entity698 complicated with @entity298 , 2 with @entity30773 , one each of left coxitis, infected medial cervical cyst, @entity221 after a V-P shunt operation, purulent @entity8174 and intractable @entity294 with @entity221 , namely, a total of 20 @entity1 aged from one month to 11 years 6 months. A @entity5443 vial which contained 1 g of @entity5443 was used in two ways, i.e., one shot intravenous injection and drip infusion. The dosage of the drug varied from 57 to 121 mg/kg/day and the administration was continued from 2 to 20 days. Clinical effects were evaluated as follows: when cardinal symptoms disappeared within 3 days it was considered to be 'excellent'; within 5 days 'good'; and no change of clinical symptoms within 5 days 'poor'. The bacteriological effect was expressed as 'eliminated', 'unchanged' and 'undetermined'. Clinical efficacy evaluated as 'excellent' occurred in 11 cases, 'good' in 8 cases and 'poor' in 1 case, the efficacy rate being 95.0%. When classified by the disease, the efficacy rate was as follows: 'good' to 'excellent' in 7 out of the 8 cases of @entity1576 , 'excellent' in all of the 3 cases of @entity293 , 'good' and 'excellent' in the 2 cases of @entity30773 and in the 2 cases of @entity298 , 'excellent' in each case of left coxitis, purulent @entity8174 and intractable @entity294 with @entity221 , 'good' in each case of infected medial cervical cyst and @entity221 with a V-P shunt operation. From the bacteriological point of view, 'eliminated' occurred in 5 cases, 'reduced' in 1 case and 'undetermined' in the 2 cases of @entity1576 , 'eliminated' in all of the 3 cases of @entity293 , 'eliminated' in 1 case and 'undetermined' in the 1 case of @entity298 , 'undetermined' in the 2 cases of @entity30773 , 'eliminated' in each case of infected medial cervical cyst and purulent @entity8174 and 'undetermined' in the other cases. Antimicrobial efficacy measured by MIC was compared with CEZ and CET, and the results were as follows: @entity5443 was inferior to the two cephalosporins for @entity794 , it was between CEZ and CET for @entity327 and @entity6747 , and @entity5443 was superior to CEZ and CET for @entity526 . All of the 3 antibiotics had poor antimicrobial efficacy for @entity796 and @entity797 . There were neither clinical side effects nor abnormal laboratory findings which were obviously attributable to @entity5443 during and after administration of the drug.

title: [Therapeutic effects of XXXX in the treatment of various infections in @entity1 (author's transl)].

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity6747 :: ('729', 'Species') :: ['H. parainfluenzae']

entities_list: @entity8174 :: ('MESH:D010309', 'Disease') :: ['parotitis']

entities_list: @entity698 :: ('MESH:D001064', 'Disease') :: ['appendicitis']

entities_list: @entity796 :: ('287', 'Species') :: ['P. aeruginosa']

entities_list: @entity298 :: ('MESH:D010538', 'Disease') :: ['peritonitis']

entities_list: @entity294 :: ('MESH:D003967', 'Disease') :: ['diarrhea']

entities_list: @entity327 :: ('727', 'Species') :: ['H. influenzae']

entities_list: @entity1576 :: ('MESH:D012131', 'Disease') :: ['acute respiratory disease', 'ARD']

entities_list: @entity12277 :: ('CHEBI:55429', 'Chemical') :: ['cephamycin']

entities_list: @entity293 :: ('MESH:D014552', 'Disease') :: ['UTI', 'urinary tract infection']

entities_list: @entity221 :: ('MESH:D005334', 'Disease') :: ['febrile illness', 'fever']

entities_list: @entity3398 :: ('MESH:D002440', 'Chemical') :: ['cefoxitin']

entities_list: @entity30773 :: ('MESH:D012541', 'Disease') :: ['scarlet fever']

answer: @entity3398 :: (MESH:D002440,Chemical) :: ['cefoxitin']


abstract: In order to ascertain the therapeutic effects of @entity3398 ( @entity5443 ), a new semisynthetic @entity12277 antibiotic, it was administered to pediatric @entity1 with several infections. There were 8 @entity1 with @entity1576 ( @entity1576 ), 3 with @entity293 ( @entity293 ), 2 with @entity698 complicated with @entity298 , 2 with @entity30773 , one each of left coxitis, infected medial cervical cyst, @entity221 after a V-P shunt operation, purulent @entity8174 and intractable @entity294 with @entity221 , namely, a total of 20 @entity1 aged from one month to 11 years 6 months. A @entity5443 vial which contained 1 g of @entity5443 was used in two ways, i.e., one shot intravenous injection and drip infusion. The dosage of the drug varied from 57 to 121 mg/kg/day and the administration was continued from 2 to 20 days. Clinical effects were evaluated as follows: when cardinal symptoms disappeared within 3 days it was considered to be 'excellent'; within 5 days 'good'; and no change of clinical symptoms within 5 days 'poor'. The bacteriological effect was expressed as 'eliminated', 'unchanged' and 'undetermined'. Clinical efficacy evaluated as 'excellent' occurred in 11 cases, 'good' in 8 cases and 'poor' in 1 case, the efficacy rate being 95.0%. When classified by the disease, the efficacy rate was as follows: 'good' to 'excellent' in 7 out of the 8 cases of @entity1576 , 'excellent' in all of the 3 cases of @entity293 , 'good' and 'excellent' in the 2 cases of @entity30773 and in the 2 cases of @entity298 , 'excellent' in each case of left coxitis, purulent @entity8174 and intractable @entity294 with @entity221 , 'good' in each case of infected medial cervical cyst and @entity221 with a V-P shunt operation. From the bacteriological point of view, 'eliminated' occurred in 5 cases, 'reduced' in 1 case and 'undetermined' in the 2 cases of @entity1576 , 'eliminated' in all of the 3 cases of @entity293 , 'eliminated' in 1 case and 'undetermined' in the 1 case of @entity298 , 'undetermined' in the 2 cases of @entity30773 , 'eliminated' in each case of infected medial cervical cyst and purulent @entity8174 and 'undetermined' in the other cases. Antimicrobial efficacy measured by MIC was compared with CEZ and CET, and the results were as follows: @entity5443 was inferior to the two cephalosporins for @entity794 , it was between CEZ and CET for @entity327 and @entity6747 , and @entity5443 was superior to CEZ and CET for @entity526 . All of the 3 antibiotics had poor antimicrobial efficacy for @entity796 and @entity797 . There were neither clinical side effects nor abnormal laboratory findings which were obviously attributable to @entity5443 during and after administration of the drug.

title: [Therapeutic effects of @entity3398 in the treatment of various infections in XXXX (author's transl)].

answer: @entity1 :: (9606,Species) :: ['children']


abstract: BACKGROUND AND OBJECTIVE: Various nonpharmacologic treatments are available for pediatric @entity490 -related functional @entity344 (AP-FGIDs). Data on efficacy and safety are scarce. The goal of this study was to summarize the evidence regarding nonpharmacologic interventions for pediatric AP-FGIDs: lifestyle interventions, dietary interventions, behavioral interventions, prebiotics and probiotics, and alternative medicine. METHODS: Searches were conducted of the Medline and Cochrane Library databases. Systematic reviews and randomized controlled trials (RCTs) concerning nonpharmacologic therapies in @entity1 (aged 3-18 years) with AP-FGIDs were included, and data were extracted on @entity1 , interventions, and outcomes. The quality of evidence was assessed by using the GRADE approach. RESULTS: Twenty-four RCTs were found that included 1390 @entity1 . Significant improvement of @entity490 was reported after hypnotherapy compared with standard care/wait-list approaches and after cognitive behavioral therapy compared with a variety of control treatments/wait-list approaches. Written self-disclosure improved @entity158 frequency at the 6-month follow-up only. Compared with placebo, @entity1905 (LGG) and VSL#3 were associated with significantly more treatment responders (LGG relative risk: 1.31 [95% confidence interval: 1.08 to 1.59]; VSL#3: P < .05). Guar gum significantly improved @entity1744 symptom frequency; however, no effect was found for other fiber supplements (relative risk: 1.17 [95% confidence interval: 0.75 to 1.81]) or a @entity1132 -free diet. Functional disability was not significantly decreased after yoga compared with a wait-list approach. No studies were found concerning lifestyle interventions; gluten-, @entity112 -, or @entity13349 -free diets; fluid intake; or prebiotics. No serious adverse effects were reported. The quality of evidence was found to be very low to moderate. CONCLUSIONS: Although high-quality studies are lacking, some evidence shows efficacy of hypnotherapy, cognitive behavioral therapy, and probiotics (LGG and VSL#3) in pediatric AP-FGIDs. Data on fiber supplements are inconclusive.

title: Nonpharmacologic Treatment of Functional XXXX : A Systematic Review.

entities_list: @entity1 :: ('9606', 'Species') :: ['participants', 'children']

entities_list: @entity344 :: ('MESH:D005767', 'Disease') :: ['gastrointestinal disorders']

entities_list: @entity13349 :: ('MESH:D002255', 'Chemical') :: ['carbonic acid']

entities_list: @entity112 :: ('MESH:D006632', 'Chemical') :: ['histamine']

entities_list: @entity1744 :: ('MESH:D043183', 'Disease') :: ['irritable bowel syndrome']

entities_list: @entity490 :: ('MESH:D015746', 'Disease') :: ['abdominal pain']

entities_list: @entity1905 :: ('568703', 'Species') :: ['Lactobacillus rhamnosus GG']

answer: @entity490 :: (MESH:D015746,Disease) :: ['Abdominal Pain Disorders']


abstract: AIM: The aim of the present study was to investigate the prognostic @entity149 (CNS) after acquired resistance to @entity470 ( @entity470 )- @entity669 kinase inhibitor (TKI) in @entity470 -mutant @entity1149 ( @entity1149 ). @entity1 AND METHODS: We defined CNS-collapse as @entity204 due to uncontrolled and progressive CNS @entity3 . Post-progression survival (PPS) after initial TKI failure and @entity9513 status were retrospectively compared in 92 @entity1 with or without CNS collapse. RESULTS: The median PPS in 32 @entity1 with CNS-collapse (16.7 months) was significantly shorter than that of 60 without (26.8 months) (p=0.0002). @entity9513 was detected in four (12%) out of the 32 CNS-collapse @entity1 and in 26 (43%) out of 60 without (p=0.0026). Median PPS in 39 @entity1 with leptomeningeal @entity3 (LM) (11.4 months) was significantly shorter versus 53 without (26.8 months) (p=0.0006). The median PPS was 25.1 months in 40 @entity1 with brain @entity3 and 11.2 months in 52 without (p=0.0387). @entity9513 was detected in 4/5 resected @entity1313 (80%) and in 1/26 cerebrospinal fluid (CSF) samples (4%) (p=0.0008). CONCLUSION: CNS-collapse represented poorer prognosis, which was associated with @entity9513 -negative status and LM. Controlling CNS @entity3 , especially LM, is important to achieve longer survival.

title: Prognostic Impact of Central Nervous System @entity3 After Acquired Resistance to XXXX -TKI: Poorer Prognosis Associated with @entity9513 -negative Status and @entity3 .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'PATIENTS']

entities_list: @entity1313 :: ('MESH:D001932', 'Disease') :: ['brain tumors']

entities_list: @entity470 :: ('1956', 'Gene') :: ['EGFR', 'epidermal growth factor receptor']

entities_list: @entity1149 :: ('MESH:D002289', 'Disease') :: ['NSCLC', 'non-small cell lung cancer']

entities_list: @entity149 :: ('MESH:D002493', 'Disease') :: ['impact of central nervous system metastases']

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['metastases']

entities_list: @entity669 :: ('CHEBI:18186', 'Chemical') :: ['tyrosine']

answer: @entity470 :: (1956,Gene) :: ['EGFR']


abstract: AIM: The aim of the present study was to investigate the prognostic @entity149 (CNS) after acquired resistance to @entity470 ( @entity470 )- @entity669 kinase inhibitor (TKI) in @entity470 -mutant @entity1149 ( @entity1149 ). @entity1 AND METHODS: We defined CNS-collapse as @entity204 due to uncontrolled and progressive CNS @entity3 . Post-progression survival (PPS) after initial TKI failure and @entity9513 status were retrospectively compared in 92 @entity1 with or without CNS collapse. RESULTS: The median PPS in 32 @entity1 with CNS-collapse (16.7 months) was significantly shorter than that of 60 without (26.8 months) (p=0.0002). @entity9513 was detected in four (12%) out of the 32 CNS-collapse @entity1 and in 26 (43%) out of 60 without (p=0.0026). Median PPS in 39 @entity1 with leptomeningeal @entity3 (LM) (11.4 months) was significantly shorter versus 53 without (26.8 months) (p=0.0006). The median PPS was 25.1 months in 40 @entity1 with brain @entity3 and 11.2 months in 52 without (p=0.0387). @entity9513 was detected in 4/5 resected @entity1313 (80%) and in 1/26 cerebrospinal fluid (CSF) samples (4%) (p=0.0008). CONCLUSION: CNS-collapse represented poorer prognosis, which was associated with @entity9513 -negative status and LM. Controlling CNS @entity3 , especially LM, is important to achieve longer survival.

title: Prognostic Impact of Central Nervous System XXXX After Acquired Resistance to @entity470 -TKI: Poorer Prognosis Associated with @entity9513 -negative Status and @entity3 .

answer: @entity3 :: (MESH:D009362,Disease) :: ['Metastases']


abstract: AIM: The aim of the present study was to investigate the prognostic @entity149 (CNS) after acquired resistance to @entity470 ( @entity470 )- @entity669 kinase inhibitor (TKI) in @entity470 -mutant @entity1149 ( @entity1149 ). @entity1 AND METHODS: We defined CNS-collapse as @entity204 due to uncontrolled and progressive CNS @entity3 . Post-progression survival (PPS) after initial TKI failure and @entity9513 status were retrospectively compared in 92 @entity1 with or without CNS collapse. RESULTS: The median PPS in 32 @entity1 with CNS-collapse (16.7 months) was significantly shorter than that of 60 without (26.8 months) (p=0.0002). @entity9513 was detected in four (12%) out of the 32 CNS-collapse @entity1 and in 26 (43%) out of 60 without (p=0.0026). Median PPS in 39 @entity1 with leptomeningeal @entity3 (LM) (11.4 months) was significantly shorter versus 53 without (26.8 months) (p=0.0006). The median PPS was 25.1 months in 40 @entity1 with brain @entity3 and 11.2 months in 52 without (p=0.0387). @entity9513 was detected in 4/5 resected @entity1313 (80%) and in 1/26 cerebrospinal fluid (CSF) samples (4%) (p=0.0008). CONCLUSION: CNS-collapse represented poorer prognosis, which was associated with @entity9513 -negative status and LM. Controlling CNS @entity3 , especially LM, is important to achieve longer survival.

title: Prognostic Impact of Central Nervous System @entity3 After Acquired Resistance to @entity470 -TKI: Poorer Prognosis Associated with @entity9513 -negative Status and XXXX .

answer: @entity3 :: (MESH:D009362,Disease) :: ['Leptomeningeal Metastases']


abstract: AIM: The aim of the present study was to investigate the prognostic @entity149 (CNS) after acquired resistance to @entity470 ( @entity470 )- @entity669 kinase inhibitor (TKI) in @entity470 -mutant @entity1149 ( @entity1149 ). @entity1 AND METHODS: We defined CNS-collapse as @entity204 due to uncontrolled and progressive CNS @entity3 . Post-progression survival (PPS) after initial TKI failure and @entity9513 status were retrospectively compared in 92 @entity1 with or without CNS collapse. RESULTS: The median PPS in 32 @entity1 with CNS-collapse (16.7 months) was significantly shorter than that of 60 without (26.8 months) (p=0.0002). @entity9513 was detected in four (12%) out of the 32 CNS-collapse @entity1 and in 26 (43%) out of 60 without (p=0.0026). Median PPS in 39 @entity1 with leptomeningeal @entity3 (LM) (11.4 months) was significantly shorter versus 53 without (26.8 months) (p=0.0006). The median PPS was 25.1 months in 40 @entity1 with brain @entity3 and 11.2 months in 52 without (p=0.0387). @entity9513 was detected in 4/5 resected @entity1313 (80%) and in 1/26 cerebrospinal fluid (CSF) samples (4%) (p=0.0008). CONCLUSION: CNS-collapse represented poorer prognosis, which was associated with @entity9513 -negative status and LM. Controlling CNS @entity3 , especially LM, is important to achieve longer survival.

title: Prognostic Impact of Central Nervous System @entity3 After Acquired Resistance to @entity470 -TKI: Poorer Prognosis Associated with XXXX -negative Status and @entity3 .

answer: @entity9513 :: (p|SUB|T|790|M,ProteinMutation) :: ['T790M']


abstract: UNASSIGNED: The upregulation of chemokine genes and the subsequent T-lymphocyte recruitment to the graft are early events in the development of @entity299 or @entity299 . In the present study, a combined immunosuppressive regimen of C-X-C motif chemokine 9 ( @entity12426 ) antibody (Ab), @entity15369 Ab and @entity20083 was used in order to reduce the infiltration of memory T lymphocytes and prolong graft survival in a retransplantation @entity19 model. BALB/c donor hearts were transplanted heterotopically into C57BL/6 @entity19 at day 28 after skin transplantation. The @entity19 were divided into four groups: i) Control (normal saline), ii) @entity12426 Ab and @entity15369 Ab [150  g; once daily (qd); intraperitoneal (ip)], iii) @entity20083 (0.2 mg/day; qd; ip) and iv) combined (2 mg/kg/day; qd; ip). Measurements of the median survival time of the cardiac grafts, histological examination, reverse transcription-quantitative polymerase chain reaction analysis, enzyme-linked immunosorbent assay and a mixed lymphocyte reaction were performed. The median graft survival time of the combined group was prolonged (9.3 days) compared with that of the control group (3.5 days) (P<0.001). Histological examination revealed that the combined treatment group graft rejection pathological score was 0.50, while the control group score was 3.62 (P<0.001). In addition, the gene expression level of @entity2047 was significantly lower and the levels of @entity1618 and @entity641 ( @entity641 ) were significantly higher in the combined group compared with those in the control group (P<0.001). Furthermore, the serum concentration levels of @entity2047 and interferon-y (IFN-y) were significantly lower (P<0.001) and the concentration of @entity1618 was significantly higher (P<0.05) in the combined group compared with those in the control group. In the mixed lymphocyte reaction, T-cell proliferation was found to be significantly lower in the combined treatment group than that in the control group (P<0.001). In conclusion, treatment with @entity12426 Ab and @entity15369 Ab or @entity20083 reduced the graft infiltration of inflammatory cells, inhibited T-cell proliferation and prolonged graft survival. The combined treatment regimen of @entity12426 Ab, @entity15369 Ab and @entity20083 was found to significantly reduce the infiltration of inflammatory cells in the graft and prolong graft survival.

title: Combination of C-X-C motif chemokine 9 and C-X-C motif chemokine 10 antibodies with XXXX prolongs the survival of cardiac retransplantation allografts in a @entity19 model.

entities_list: @entity641 :: ('21803(Tax:10090)', 'Gene') :: ['TGF-b', 'transforming growth factor-b']

entities_list: @entity299 :: ('MESH:D006331', 'Disease') :: ['acute cardiac transplant rejection', 'cardiac allograft vasculopathy']

answer: @entity20083 :: (MESH:C098720,Chemical) :: ['FTY720']


abstract: UNASSIGNED: The upregulation of chemokine genes and the subsequent T-lymphocyte recruitment to the graft are early events in the development of @entity299 or @entity299 . In the present study, a combined immunosuppressive regimen of C-X-C motif chemokine 9 ( @entity12426 ) antibody (Ab), @entity15369 Ab and @entity20083 was used in order to reduce the infiltration of memory T lymphocytes and prolong graft survival in a retransplantation @entity19 model. BALB/c donor hearts were transplanted heterotopically into C57BL/6 @entity19 at day 28 after skin transplantation. The @entity19 were divided into four groups: i) Control (normal saline), ii) @entity12426 Ab and @entity15369 Ab [150  g; once daily (qd); intraperitoneal (ip)], iii) @entity20083 (0.2 mg/day; qd; ip) and iv) combined (2 mg/kg/day; qd; ip). Measurements of the median survival time of the cardiac grafts, histological examination, reverse transcription-quantitative polymerase chain reaction analysis, enzyme-linked immunosorbent assay and a mixed lymphocyte reaction were performed. The median graft survival time of the combined group was prolonged (9.3 days) compared with that of the control group (3.5 days) (P<0.001). Histological examination revealed that the combined treatment group graft rejection pathological score was 0.50, while the control group score was 3.62 (P<0.001). In addition, the gene expression level of @entity2047 was significantly lower and the levels of @entity1618 and @entity641 ( @entity641 ) were significantly higher in the combined group compared with those in the control group (P<0.001). Furthermore, the serum concentration levels of @entity2047 and interferon-y (IFN-y) were significantly lower (P<0.001) and the concentration of @entity1618 was significantly higher (P<0.05) in the combined group compared with those in the control group. In the mixed lymphocyte reaction, T-cell proliferation was found to be significantly lower in the combined treatment group than that in the control group (P<0.001). In conclusion, treatment with @entity12426 Ab and @entity15369 Ab or @entity20083 reduced the graft infiltration of inflammatory cells, inhibited T-cell proliferation and prolonged graft survival. The combined treatment regimen of @entity12426 Ab, @entity15369 Ab and @entity20083 was found to significantly reduce the infiltration of inflammatory cells in the graft and prolong graft survival.

title: Combination of C-X-C motif chemokine 9 and C-X-C motif chemokine 10 antibodies with @entity20083 prolongs the survival of cardiac retransplantation allografts in a XXXX model.

answer: @entity19 :: (10090,Species) :: ['mouse']


abstract: UNASSIGNED: The aim of the present study was to assess the effectiveness and safety of endovascular interventional therapy, which is mechanical clot disruption combined with intrasinus thrombolytic therapy with recombinant @entity1456 (rt-PA), for severe @entity50 ( @entity50 ). The records of eight @entity1 with @entity50 confirmed by computed tomography, magnetic resonance imaging (MRI), magnetic resonance venography (MRV) and/or digital subtraction angiography were analyzed. Of the eight cases, the Glasgow @entity772 Scale (GCS) scores were between 4 and 9 with a mean value of 8.3  2.7. All the @entity1 had @entity1188 and two cases had @entity932 . Mechanical clot destruction combined with intrasinus thrombolytic therapy with rt-PA was performed under general anesthesia. Intravenous heparin therapy and intracerebral pressure control were applied during this period. One @entity1 succumbed and the other seven @entity1 showed good treatment efficacy. The GCS scores of the seven @entity1 reverted to 15 upon discharge from the Northern Jiangsu @entity1 's Hospital (Yangzhou, China). With regard to the modified Rankin score of the seven @entity1 three months following surgery, six @entity1 scored 0 and one @entity1 scored 1. MRI and MRV follow-up examinations were performed for 3-15 months. Complete recanalization of the criminal sinus, which refer to the sinus attributable to the @entity1188 or @entity548 , was observed in five cases and partial recanalization was observed in two cases. Symptoms were monitored for 3-24 months and no recurrence was observed. Therefore, mechanical thrombectomy combined with intrasinus thrombolytic therapy with rt-PA is safe and effective for @entity1 with severe @entity50 .

title: Mechanical thrombectomy combined with recombinant @entity1456 thrombolysis in the venous sinus for the treatment of severe XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient', 'People']

entities_list: @entity932 :: ('MESH:D020300', 'Disease') :: ['intracranial hemorrhagic infarcts']

entities_list: @entity548 :: ('MESH:D006470', 'Disease') :: ['hemorrhage']

entities_list: @entity1456 :: ('100128998', 'Gene') :: ['tissue plasminogen activator']

entities_list: @entity1188 :: ('MESH:D007238', 'Disease') :: ['venous infarction', 'infarction']

entities_list: @entity50 :: ('MESH:D012851', 'Disease') :: ['cerebral venous sinus thrombosis', 'CVST']

answer: @entity50 :: (MESH:D012851,Disease) :: ['cerebral venous sinus thrombosis']


abstract: UNASSIGNED: The aim of the present study was to assess the effectiveness and safety of endovascular interventional therapy, which is mechanical clot disruption combined with intrasinus thrombolytic therapy with recombinant @entity1456 (rt-PA), for severe @entity50 ( @entity50 ). The records of eight @entity1 with @entity50 confirmed by computed tomography, magnetic resonance imaging (MRI), magnetic resonance venography (MRV) and/or digital subtraction angiography were analyzed. Of the eight cases, the Glasgow @entity772 Scale (GCS) scores were between 4 and 9 with a mean value of 8.3  2.7. All the @entity1 had @entity1188 and two cases had @entity932 . Mechanical clot destruction combined with intrasinus thrombolytic therapy with rt-PA was performed under general anesthesia. Intravenous heparin therapy and intracerebral pressure control were applied during this period. One @entity1 succumbed and the other seven @entity1 showed good treatment efficacy. The GCS scores of the seven @entity1 reverted to 15 upon discharge from the Northern Jiangsu @entity1 's Hospital (Yangzhou, China). With regard to the modified Rankin score of the seven @entity1 three months following surgery, six @entity1 scored 0 and one @entity1 scored 1. MRI and MRV follow-up examinations were performed for 3-15 months. Complete recanalization of the criminal sinus, which refer to the sinus attributable to the @entity1188 or @entity548 , was observed in five cases and partial recanalization was observed in two cases. Symptoms were monitored for 3-24 months and no recurrence was observed. Therefore, mechanical thrombectomy combined with intrasinus thrombolytic therapy with rt-PA is safe and effective for @entity1 with severe @entity50 .

title: Mechanical thrombectomy combined with recombinant XXXX thrombolysis in the venous sinus for the treatment of severe @entity50 .

answer: @entity1456 :: (100128998,Gene) :: ['tissue plasminogen activator']


abstract: Outpatient ambulatory EEG is more cost-effective than inpatient EEG telemetry and may provide adequate @entity410 localization in a presurgical evaluation. A 51-year-old right-handed male had been unable to work or drive since the age of 35 due to intractable partial onset @entity302 . A 72-hour outpatient ambulatory EEG recorded 18 @entity410 from the right temporal region. No @entity302 was seen in the left hemisphere. Magnetic resonance imaging showed right mesial @entity1463 as well as an area of @entity9872 at the medial inferior right temporal lobe. Neuropsychological assessment found that the @entity1 was a good neurosurgery candidate. At this point, the @entity1 was considered to be a candidate for a right temporal lobectomy. A standard right temporal lobectomy was performed. The @entity1 has been @entity410 -free for 10  months after the surgery. Follow-up EEGs show no @entity302 . The @entity1 is preparing to go back to work, and his driver's license was reinstated 9  months postsurgery. Neuropsychological reassessment is pending, but no apparent change in cognition has been noticed by the @entity1 or his family. Cases with a high congruence between diagnostic imaging and the EEG abnormalities identified in the portable EEG may provide enough information regarding @entity410 frequency and localization to eliminate the need for inpatient EEG telemetry in the evaluation of @entity1 for @entity302 surgery. We believe that the use of aEEG in preoperative planning should be restricted to cases of TLE and to @entity1 with a high frequency of @entity410 .

title: Outpatient ambulatory EEG as an option for XXXX surgery evaluation instead of inpatient EEG telemetry.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity410 :: ('MESH:D012640', 'Disease') :: ['seizure', 'seizures']

entities_list: @entity1463 :: ('MESH:D012598', 'Disease') :: ['temporal sclerosis']

entities_list: @entity302 :: ('MESH:D004827', 'Disease') :: ['epilepsy', 'epileptiform activity']

entities_list: @entity9872 :: ('MESH:D004678', 'Disease') :: ['encephalomalacia']

answer: @entity302 :: (MESH:D004827,Disease) :: ['epilepsy']


abstract: INTRODUCTION: The purpose of this study was to determine the proportion of symptomatic recurrence following initial non-operative management of @entity5990 in the elderly and to test possible predictors. METHODS: This is a single institution retrospective chart review of @entity1  65 years and older with an initial hospital visit (V1) for symptomatic @entity5990 , over a 4-year period. @entity1 with initial "non-operative" management were defined as those without surgery @entity9485 and without elective surgery at visit 2 (V2). Baseline characteristics included age, sex, Charlson comorbidity index (CCI), diagnosis, and interventions (ERCP or cholecystostomy) @entity9485 . Outcomes assessed over 1  year were as follows: recurrence (any ER/admission visit following V1), surgery, complications, and mortality. A survival analysis using a Cox proportional hazards model was performed to assess predictors of recurrence. RESULTS: There were 195 @entity1 initially treated non-operatively @entity9485 . Mean age was 78.3      7.8  years, 45.6  % were male, and the mean CCI was 2.1      1.9. @entity9485 , 54.4  % had a diagnosis of @entity253 or @entity2679 , while 45.6  % had a diagnosis of @entity255 , @entity788 , or @entity2877 . 39.5  % underwent ERCP or cholecystostomy. Excluding 10 @entity1 who died @entity9485 , 31.3  % of @entity1 had a recurrence over the study period. Among these, 43.5  % had emergency surgery, 34.8  % had complications, and 4.3  % died. Median time to first recurrence was 2  months (range 6  days-4.8  months). Intervention @entity9485 was associated with a lower probability of recurrence (HR 0.3, CI [0.14-0.65]). CONCLUSION: One-third of elderly @entity1 will develop a recurrence following non-operative management of symptomatic @entity253 . These recurrences are associated with significant rates of emergency surgery and morbidity. Percutaneous or endoscopic therapies may decrease the risk of recurrence.

title: Recurrence of XXXX following non-operative management in elderly @entity1 .

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity788 :: ('MESH:D010190', 'Disease') :: ['pancreatitis']

entities_list: @entity5990 :: ('MESH:D042882', 'Disease') :: ['gallstone disease']

entities_list: @entity2679 :: ('MESH:D002764', 'Disease') :: ['cholecystitis']

entities_list: @entity253 :: ('MESH:D001660', 'Disease') :: ['biliary disease', 'biliary colic']

entities_list: @entity255 :: ('MESH:D002761', 'Disease') :: ['cholangitis']

entities_list: @entity2877 :: ('MESH:D042883', 'Disease') :: ['choledocholithiasis']

answer: @entity253 :: (MESH:D001660,Disease) :: ['biliary disease']


abstract: INTRODUCTION: The purpose of this study was to determine the proportion of symptomatic recurrence following initial non-operative management of @entity5990 in the elderly and to test possible predictors. METHODS: This is a single institution retrospective chart review of @entity1  65 years and older with an initial hospital visit (V1) for symptomatic @entity5990 , over a 4-year period. @entity1 with initial "non-operative" management were defined as those without surgery @entity9485 and without elective surgery at visit 2 (V2). Baseline characteristics included age, sex, Charlson comorbidity index (CCI), diagnosis, and interventions (ERCP or cholecystostomy) @entity9485 . Outcomes assessed over 1  year were as follows: recurrence (any ER/admission visit following V1), surgery, complications, and mortality. A survival analysis using a Cox proportional hazards model was performed to assess predictors of recurrence. RESULTS: There were 195 @entity1 initially treated non-operatively @entity9485 . Mean age was 78.3      7.8  years, 45.6  % were male, and the mean CCI was 2.1      1.9. @entity9485 , 54.4  % had a diagnosis of @entity253 or @entity2679 , while 45.6  % had a diagnosis of @entity255 , @entity788 , or @entity2877 . 39.5  % underwent ERCP or cholecystostomy. Excluding 10 @entity1 who died @entity9485 , 31.3  % of @entity1 had a recurrence over the study period. Among these, 43.5  % had emergency surgery, 34.8  % had complications, and 4.3  % died. Median time to first recurrence was 2  months (range 6  days-4.8  months). Intervention @entity9485 was associated with a lower probability of recurrence (HR 0.3, CI [0.14-0.65]). CONCLUSION: One-third of elderly @entity1 will develop a recurrence following non-operative management of symptomatic @entity253 . These recurrences are associated with significant rates of emergency surgery and morbidity. Percutaneous or endoscopic therapies may decrease the risk of recurrence.

title: Recurrence of @entity253 following non-operative management in elderly XXXX .

answer: @entity1 :: (9606,Species) :: ['patients']


abstract: BACKGROUND: The aim of the present study was to investigate the efficacy of intracorporeal reinforcing sutures for preventing @entity834 ( @entity834 ) after laparoscopic surgery for @entity5 . METHODS: This was a retrospective single-institution study consisting of 201 consecutive @entity1 who underwent laparoscopic proctectomy with double-stapling anastomosis for primary @entity5 between August 2007 and December 2013. The data for @entity1 who received intracorporeal reinforcing sutures were compared with those of @entity1 who did not receive reinforcing sutures. @entity1 -, @entity5 - and surgery-related variables were collected and examined using univariate and multivariate analyses. RESULTS: The overall incidence of @entity834 was 9.0  % (18/201). No significant correlations were observed between the various clinicopathological factors and the use of reinforcing sutures. The multivariate analyses revealed the distance of the @entity5 from the anal verge, @entity5 size and presence of reinforcing sutures to be independent risk factors for @entity834 . We classified the @entity1 into two risk groups using a combination of the @entity5 site and @entity5 size: a low-risk group ( @entity1 without any risk factors, n  =  134) and a high-risk group ( @entity1 with one or two risk factors, n  =  67). The frequency of @entity834 was significantly lower (p  <  0.02) in the @entity1 treated with reinforcing sutures than in those treated without reinforcing sutures in the high-risk group. However, no significant differences were observed in the low-risk group. CONCLUSIONS: The use of intracorporeal reinforcing sutures may reduce the incidence of @entity834 . A prospective randomized trial is required to evaluate the effects of reinforcing sutures in preventing @entity834 .

title: Efficacy of intracorporeal reinforcing sutures for XXXX after laparoscopic surgery for @entity5 .

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'rectal cancer']

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'Patient']

entities_list: @entity834 :: ('MESH:D057868', 'Disease') :: ['AL', 'anastomotic leakage']

answer: @entity834 :: (MESH:D057868,Disease) :: ['anastomotic leakage']


abstract: BACKGROUND: The aim of the present study was to investigate the efficacy of intracorporeal reinforcing sutures for preventing @entity834 ( @entity834 ) after laparoscopic surgery for @entity5 . METHODS: This was a retrospective single-institution study consisting of 201 consecutive @entity1 who underwent laparoscopic proctectomy with double-stapling anastomosis for primary @entity5 between August 2007 and December 2013. The data for @entity1 who received intracorporeal reinforcing sutures were compared with those of @entity1 who did not receive reinforcing sutures. @entity1 -, @entity5 - and surgery-related variables were collected and examined using univariate and multivariate analyses. RESULTS: The overall incidence of @entity834 was 9.0  % (18/201). No significant correlations were observed between the various clinicopathological factors and the use of reinforcing sutures. The multivariate analyses revealed the distance of the @entity5 from the anal verge, @entity5 size and presence of reinforcing sutures to be independent risk factors for @entity834 . We classified the @entity1 into two risk groups using a combination of the @entity5 site and @entity5 size: a low-risk group ( @entity1 without any risk factors, n  =  134) and a high-risk group ( @entity1 with one or two risk factors, n  =  67). The frequency of @entity834 was significantly lower (p  <  0.02) in the @entity1 treated with reinforcing sutures than in those treated without reinforcing sutures in the high-risk group. However, no significant differences were observed in the low-risk group. CONCLUSIONS: The use of intracorporeal reinforcing sutures may reduce the incidence of @entity834 . A prospective randomized trial is required to evaluate the effects of reinforcing sutures in preventing @entity834 .

title: Efficacy of intracorporeal reinforcing sutures for @entity834 after laparoscopic surgery for XXXX .

answer: @entity5 :: (MESH:D009369,Disease) :: ['rectal cancer']


abstract: BACKGROUND: As a Chinese Traditional Medicine product, Kuntai capsule could improve the peri-menopausal symptoms in postmenopausal @entity1 . But it is still not clear whether Kuntai capsule has a good effect on alleviating peri-menopausal symptoms induced by @entity4396 agonist ( @entity1176 -a) treatment. The purpose of this study was to investigate the clinical effectiveness and safety of Kuntai capsule, on peri-menopausal symptoms in @entity46 ( @entity46 ) @entity1 , with postoperative @entity1176 -a treatment. METHODS: Ninety @entity46 @entity42 @entity1 with postoperative @entity1176 -a administration were enrolled in the study, and were randomly divided into Kuntai group, @entity11347 group, or blank Control group. The therapeutic strategy in Kuntai group was 4 Kuntai capsules tid,po for 12 weeks after the first @entity1176 -a injection, while @entity11347 2.5 mg qd, po for 12 weeks in @entity11347 group. There was no drug addition in Control group. Climacteric complaints were evaluated by Kupperman menopausal index (KMI) and hot flash/sweating score. @entity177 , lipid profile, serum sex hormone levels and endometrial thickness were measured, and the frequency of adverse events in Kuntai and @entity11347 groups was recorded. RESULTS: (1) Before @entity1176 -a therapy, the baseline parameter results were comparable in the three groups (P > 0.05). (2) After @entity1176 -a therapy, KMI and hot flash/sweating scores in all the three groups increased significantly (P < 0.05). At the 4 th week after @entity1176 -a therapy, KMI and hot flash/sweating score results were as follows: Control group > Kuntai group > @entity11347 group (P < 0.05); at the 8 th and 12 th week after @entity1176 -a therapy, KMI and hot flash/sweating score in Control group were significantly higher than the other two groups (P < 0.05), and no significant difference was identified between Kuntai and @entity11347 group (P > 0.05). (3) No statistical change took place in the liver and renal functions and lipid profile in all the three groups after the treatment (P > 0.05). (4) The posttherapeutic serum follicle-stimulating hormone (FSH), luteinizing hormone (LH) and @entity53 (E2) level and endometrial thickness decreased significantly in all the three groups (P < 0.05). After therapy, serum E2 level in @entity11347 group was obviously higher than the other two groups (P < 0.05), while FSH and LH levels were obviously lower (P < 0.05). (5) The incidence of @entity3556 , breast distending pain in Tibolne group was obviously higher than Kuntai group (P < 0. 05). CONCLUSIONS: Kuntai capsule is effective on the peri-menopausal symptoms induced by postoperative @entity1176 -a administration to @entity46 @entity1 , although its clinical effect might be a few weeks later than @entity11347 . Kuntai capsule might be a little safer than @entity11347 tablet.

title: Efficacy and Safety Investigation of Kuntai Capsule for the Add-back Therapy of XXXX Agonist Administration to Endometriosis @entity1 : A Randomized, Double-blind, Blank- and @entity11347 -controlled Study.

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'patients']

entities_list: @entity4396 :: ('2796', 'Gene') :: ['gonadotropin releasing hormone']

entities_list: @entity3556 :: ('MESH:D014592', 'Disease') :: ['vaginal bleeding']

entities_list: @entity53 :: ('MESH:D004958', 'Chemical') :: ['estradiol']

entities_list: @entity177 :: ('MESH:D051437', 'Disease') :: ['Liver and renal functions']

entities_list: @entity42 :: ('MESH:D010048', 'Disease') :: ['ovarian cyst']

entities_list: @entity46 :: ('MESH:D004715', 'Disease') :: ['EMS', 'endometriosis']

answer: @entity4396 :: (2796,Gene) :: ['Gonadotropin Releasing Hormone']


abstract: BACKGROUND: As a Chinese Traditional Medicine product, Kuntai capsule could improve the peri-menopausal symptoms in postmenopausal @entity1 . But it is still not clear whether Kuntai capsule has a good effect on alleviating peri-menopausal symptoms induced by @entity4396 agonist ( @entity1176 -a) treatment. The purpose of this study was to investigate the clinical effectiveness and safety of Kuntai capsule, on peri-menopausal symptoms in @entity46 ( @entity46 ) @entity1 , with postoperative @entity1176 -a treatment. METHODS: Ninety @entity46 @entity42 @entity1 with postoperative @entity1176 -a administration were enrolled in the study, and were randomly divided into Kuntai group, @entity11347 group, or blank Control group. The therapeutic strategy in Kuntai group was 4 Kuntai capsules tid,po for 12 weeks after the first @entity1176 -a injection, while @entity11347 2.5 mg qd, po for 12 weeks in @entity11347 group. There was no drug addition in Control group. Climacteric complaints were evaluated by Kupperman menopausal index (KMI) and hot flash/sweating score. @entity177 , lipid profile, serum sex hormone levels and endometrial thickness were measured, and the frequency of adverse events in Kuntai and @entity11347 groups was recorded. RESULTS: (1) Before @entity1176 -a therapy, the baseline parameter results were comparable in the three groups (P > 0.05). (2) After @entity1176 -a therapy, KMI and hot flash/sweating scores in all the three groups increased significantly (P < 0.05). At the 4 th week after @entity1176 -a therapy, KMI and hot flash/sweating score results were as follows: Control group > Kuntai group > @entity11347 group (P < 0.05); at the 8 th and 12 th week after @entity1176 -a therapy, KMI and hot flash/sweating score in Control group were significantly higher than the other two groups (P < 0.05), and no significant difference was identified between Kuntai and @entity11347 group (P > 0.05). (3) No statistical change took place in the liver and renal functions and lipid profile in all the three groups after the treatment (P > 0.05). (4) The posttherapeutic serum follicle-stimulating hormone (FSH), luteinizing hormone (LH) and @entity53 (E2) level and endometrial thickness decreased significantly in all the three groups (P < 0.05). After therapy, serum E2 level in @entity11347 group was obviously higher than the other two groups (P < 0.05), while FSH and LH levels were obviously lower (P < 0.05). (5) The incidence of @entity3556 , breast distending pain in Tibolne group was obviously higher than Kuntai group (P < 0. 05). CONCLUSIONS: Kuntai capsule is effective on the peri-menopausal symptoms induced by postoperative @entity1176 -a administration to @entity46 @entity1 , although its clinical effect might be a few weeks later than @entity11347 . Kuntai capsule might be a little safer than @entity11347 tablet.

title: Efficacy and Safety Investigation of Kuntai Capsule for the Add-back Therapy of @entity4396 Agonist Administration to Endometriosis @entity1 : A Randomized, Double-blind, Blank- and XXXX -controlled Study.

answer: @entity11347 :: (MESH:C027385,Chemical) :: ['Tibolone']


abstract: BACKGROUND: As a Chinese Traditional Medicine product, Kuntai capsule could improve the peri-menopausal symptoms in postmenopausal @entity1 . But it is still not clear whether Kuntai capsule has a good effect on alleviating peri-menopausal symptoms induced by @entity4396 agonist ( @entity1176 -a) treatment. The purpose of this study was to investigate the clinical effectiveness and safety of Kuntai capsule, on peri-menopausal symptoms in @entity46 ( @entity46 ) @entity1 , with postoperative @entity1176 -a treatment. METHODS: Ninety @entity46 @entity42 @entity1 with postoperative @entity1176 -a administration were enrolled in the study, and were randomly divided into Kuntai group, @entity11347 group, or blank Control group. The therapeutic strategy in Kuntai group was 4 Kuntai capsules tid,po for 12 weeks after the first @entity1176 -a injection, while @entity11347 2.5 mg qd, po for 12 weeks in @entity11347 group. There was no drug addition in Control group. Climacteric complaints were evaluated by Kupperman menopausal index (KMI) and hot flash/sweating score. @entity177 , lipid profile, serum sex hormone levels and endometrial thickness were measured, and the frequency of adverse events in Kuntai and @entity11347 groups was recorded. RESULTS: (1) Before @entity1176 -a therapy, the baseline parameter results were comparable in the three groups (P > 0.05). (2) After @entity1176 -a therapy, KMI and hot flash/sweating scores in all the three groups increased significantly (P < 0.05). At the 4 th week after @entity1176 -a therapy, KMI and hot flash/sweating score results were as follows: Control group > Kuntai group > @entity11347 group (P < 0.05); at the 8 th and 12 th week after @entity1176 -a therapy, KMI and hot flash/sweating score in Control group were significantly higher than the other two groups (P < 0.05), and no significant difference was identified between Kuntai and @entity11347 group (P > 0.05). (3) No statistical change took place in the liver and renal functions and lipid profile in all the three groups after the treatment (P > 0.05). (4) The posttherapeutic serum follicle-stimulating hormone (FSH), luteinizing hormone (LH) and @entity53 (E2) level and endometrial thickness decreased significantly in all the three groups (P < 0.05). After therapy, serum E2 level in @entity11347 group was obviously higher than the other two groups (P < 0.05), while FSH and LH levels were obviously lower (P < 0.05). (5) The incidence of @entity3556 , breast distending pain in Tibolne group was obviously higher than Kuntai group (P < 0. 05). CONCLUSIONS: Kuntai capsule is effective on the peri-menopausal symptoms induced by postoperative @entity1176 -a administration to @entity46 @entity1 , although its clinical effect might be a few weeks later than @entity11347 . Kuntai capsule might be a little safer than @entity11347 tablet.

title: Efficacy and Safety Investigation of Kuntai Capsule for the Add-back Therapy of @entity4396 Agonist Administration to Endometriosis XXXX : A Randomized, Double-blind, Blank- and @entity11347 -controlled Study.

answer: @entity1 :: (9606,Species) :: ['Patients']


abstract: BACKGROUND: In China, @entity5744 ( @entity5744 ) aspiration, a major cause of emergency episode and @entity204 in @entity1 , remains a challenge for anesthetic management. Here, we share our experience and discuss the anesthetic consideration and management of @entity1 with @entity5744 aspiration. METHODS: This was a single-institution retrospective study in @entity1 with an inhaled foreign body between 1991 and 2010 that focused on the complications following @entity2003 ( @entity2003 ). Data including the clinical characteristics of @entity1 and @entity5744 , anesthetic method, and postoperative severe complications were analyzed by different periods. RESULTS: During the 20-year study period, the charts of 3149 @entity1 who underwent @entity2003 for suspected inhaled @entity5744 were reviewed. There were 2079 male and 1070 female @entity1 (1.94:1). A nut (84%) was the most commonly inhaled object. The study revealed a 9% (n = 284) overall rate of severe @entity260 related to severe @entity519 , @entity4 , complete @entity8822 , pneumothorax, @entity1347 , and death with incidences of 3.2%, 0.9%, 1.3%, 0.3%, 0.3%, and 0.1%, respectively. The rates of preoperative @entity73 , negative findings of @entity5744 , and adverse postoperative events have been on the rise in the past 5 years. CONCLUSIONS: The survey results confirmed that @entity519 remains the most common @entity260 in different periods. Both controlled ventilation and spontaneous ventilation were effective during the @entity2003 extraction of the foreign body at our hospital in the modern technique period. An active respiratory symptom was commonly seen in the groups with negative findings.

title: A time series observation of chinese @entity1 undergoing XXXX for an inhaled foreign body: 3149 cases in 1991-2010.

entities_list: @entity1 :: ('9606', 'Species') :: ['children', 'patients']

entities_list: @entity2003 :: ('MESH:D009127', 'Disease') :: ['RB', 'rigid bronchoscopy']

entities_list: @entity4 :: ('MESH:D004487', 'Disease') :: ['laryngeal edema']

entities_list: @entity1347 :: ('MESH:C537775', 'Disease') :: ['total segmental atelectasis']

entities_list: @entity73 :: ('MESH:D003072', 'Disease') :: ['airway impairment']

entities_list: @entity5744 :: ('MESH:D005547', 'Disease') :: ['tracheobronchial foreign body', 'TFB']

entities_list: @entity260 :: ('MESH:D011183', 'Disease') :: ['postoperative complications', 'postoperative complication']

entities_list: @entity519 :: ('MESH:D000860', 'Disease') :: ['hypoxemia']

entities_list: @entity204 :: ('MESH:D003643', 'Disease') :: ['accident death']

entities_list: @entity8822 :: ('MESH:D007826', 'Disease') :: ['laryngospasm']

answer: @entity2003 :: (MESH:D009127,Disease) :: ['rigid bronchoscopy']


abstract: BACKGROUND: In China, @entity5744 ( @entity5744 ) aspiration, a major cause of emergency episode and @entity204 in @entity1 , remains a challenge for anesthetic management. Here, we share our experience and discuss the anesthetic consideration and management of @entity1 with @entity5744 aspiration. METHODS: This was a single-institution retrospective study in @entity1 with an inhaled foreign body between 1991 and 2010 that focused on the complications following @entity2003 ( @entity2003 ). Data including the clinical characteristics of @entity1 and @entity5744 , anesthetic method, and postoperative severe complications were analyzed by different periods. RESULTS: During the 20-year study period, the charts of 3149 @entity1 who underwent @entity2003 for suspected inhaled @entity5744 were reviewed. There were 2079 male and 1070 female @entity1 (1.94:1). A nut (84%) was the most commonly inhaled object. The study revealed a 9% (n = 284) overall rate of severe @entity260 related to severe @entity519 , @entity4 , complete @entity8822 , pneumothorax, @entity1347 , and death with incidences of 3.2%, 0.9%, 1.3%, 0.3%, 0.3%, and 0.1%, respectively. The rates of preoperative @entity73 , negative findings of @entity5744 , and adverse postoperative events have been on the rise in the past 5 years. CONCLUSIONS: The survey results confirmed that @entity519 remains the most common @entity260 in different periods. Both controlled ventilation and spontaneous ventilation were effective during the @entity2003 extraction of the foreign body at our hospital in the modern technique period. An active respiratory symptom was commonly seen in the groups with negative findings.

title: A time series observation of chinese XXXX undergoing @entity2003 for an inhaled foreign body: 3149 cases in 1991-2010.

answer: @entity1 :: (9606,Species) :: ['children']


abstract: UNASSIGNED: Sequential use of endocrine agents is common in @entity1782 ( @entity1782 )-positive @entity0 ( @entity0 ). In premenopausal @entity1 with @entity0 , tamoxifen and/or a luteinizing hormone-releasing hormone (LH-RH) agonist are options for endocrine treatment. Meta-analysis showed that the combination of the two agents is superior to either monotherapy. Under ovarian ablation or function-suppression, an agent used to treat postmenopausal @entity1 , such as the @entity11163 ( @entity11163 ), fulvestrant, becomes possible as a subsequent therapy. In postmenopausal @entity1 , endocrine treatment options are widely available and an optimal sequence has not yet to be determined. Options for first-line therapy of metastatic disease include an @entity11163 for @entity1 who have received adjuvant tamoxifen, or tamoxifen for @entity1 who have received adjuvant @entity11163 . In addition, data suggest that fulvestrant is a promising therapeutic option that has proven efficacy in the treatment of postmenopausal @entity1 with @entity0 . Other agents that may be used in the sequence include a steroidal @entity11163 or a progestin. Furthermore, estrogen additive therapy by with diethylstilbestrol or ethinylestradiol has recently been revived and showed a high response rate as a salvage endocrine therapy, although its mechanism of action is still unclear. Thus, sequential use of endocrine therapies, especially the use of a subsequent therapy with a different mechanism of action to the prior therapy, has a beneficial effect in maintaining a good quality of life and extending survival for @entity0 with hormone responsiveness.

title: Clinical benefit of sequential use of endocrine therapies for XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'patients']

entities_list: @entity11163 :: ('MESH:C537436', 'Disease') :: ['AI', 'aromatase inhibitor']

entities_list: @entity1782 :: ('2099', 'Gene') :: ['ER', 'estrogen receptor']

entities_list: @entity0 :: ('MESH:D001943', 'Disease') :: ['metastatic breast cancer', 'MBC']

answer: @entity0 :: (MESH:D001943,Disease) :: ['metastatic breast cancer']


abstract: @entity120 ( @entity120 ) is a progressive disease that, if left untreated, eventually leads to @entity712 and @entity204 . @entity8577 (PAP) in @entity1 with @entity120 is mainly caused by an increase in pulmonary vascular resistance (PVR). Sustained vasoconstriction and excessive @entity6980 are two major causes for elevated PVR in @entity1 with @entity120 . @entity6980 is mediated by increased proliferation of pulmonary arterial smooth muscle cells (PASMC) due to PASMC dedifferentiation from a contractile or quiescent phenotype to a proliferative or synthetic phenotype. Increased cytosolic @entity141 concentration ([ @entity141 ]cyt) in PASMC is a key stimulus for cell proliferation and this phenotypic transition. Voltage-dependent @entity141 entry (VDCE) and store-operated @entity141 entry (SOCE) are important mechanisms for controlling [ @entity141 ]cyt. Stromal interacting molecule proteins (e.g., @entity19148 ) and @entity42801 both contribute to SOCE and we have previously shown that @entity19148 and @entity42801 , specifically, are upregulated in PASMC from @entity1 with idiopathic @entity120 and from animals with @entity120 in comparison to normal controls. In this study, we show that @entity19148 and @entity42801 are upregulated in proliferating PASMC compared with contractile phenotype of PASMC. Additionally, a switch in @entity141 regulation is observed in correlation with a phenotypic transition from contractile PASMC to proliferative PASMC. PASMC in a contractile phenotype or state have increased VDCE, while in the proliferative phenotype or state PASMC have increased SOCE. The data from this study indicate that upregulation of @entity19148 and @entity42801 is involved in the phenotypic transition of PASMC from a contractile state to a proliferative state; the enhanced SOCE due to upregulation of @entity19148 and @entity42801 plays an important role in PASMC proliferation.

title: Upregulated expression of XXXX , TRPC6, and @entity42801 contributes to the transition of pulmonary arterial smooth muscle cells from a contractile to proliferative phenotype.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity712 :: ('MESH:D006333', 'Disease') :: ['right heart failure']

entities_list: @entity120 :: ('MESH:D006976', 'Disease') :: ['PAH', 'experimental pulmonary hypertension', 'Pulmonary arterial hypertension']

entities_list: @entity8577 :: ('MESH:D065627', 'Disease') :: ['Elevated pulmonary arterial pressure']

entities_list: @entity6980 :: ('MESH:D066253', 'Disease') :: ['pulmonary vascular remodeling', 'Excessive pulmonary vascular remodeling']

answer: @entity19148 :: (57620,Gene) :: ['STIM2']


abstract: @entity120 ( @entity120 ) is a progressive disease that, if left untreated, eventually leads to @entity712 and @entity204 . @entity8577 (PAP) in @entity1 with @entity120 is mainly caused by an increase in pulmonary vascular resistance (PVR). Sustained vasoconstriction and excessive @entity6980 are two major causes for elevated PVR in @entity1 with @entity120 . @entity6980 is mediated by increased proliferation of pulmonary arterial smooth muscle cells (PASMC) due to PASMC dedifferentiation from a contractile or quiescent phenotype to a proliferative or synthetic phenotype. Increased cytosolic @entity141 concentration ([ @entity141 ]cyt) in PASMC is a key stimulus for cell proliferation and this phenotypic transition. Voltage-dependent @entity141 entry (VDCE) and store-operated @entity141 entry (SOCE) are important mechanisms for controlling [ @entity141 ]cyt. Stromal interacting molecule proteins (e.g., @entity19148 ) and @entity42801 both contribute to SOCE and we have previously shown that @entity19148 and @entity42801 , specifically, are upregulated in PASMC from @entity1 with idiopathic @entity120 and from animals with @entity120 in comparison to normal controls. In this study, we show that @entity19148 and @entity42801 are upregulated in proliferating PASMC compared with contractile phenotype of PASMC. Additionally, a switch in @entity141 regulation is observed in correlation with a phenotypic transition from contractile PASMC to proliferative PASMC. PASMC in a contractile phenotype or state have increased VDCE, while in the proliferative phenotype or state PASMC have increased SOCE. The data from this study indicate that upregulation of @entity19148 and @entity42801 is involved in the phenotypic transition of PASMC from a contractile state to a proliferative state; the enhanced SOCE due to upregulation of @entity19148 and @entity42801 plays an important role in PASMC proliferation.

title: Upregulated expression of @entity19148 , TRPC6, and XXXX contributes to the transition of pulmonary arterial smooth muscle cells from a contractile to proliferative phenotype.

answer: @entity42801 :: (80228,Gene) :: ['Orai2']


abstract: Xyloglucan is a polysaccharide that has important roles in the formation and function of the walls that surround growing land plant cells. Many of these plants synthesize xyloglucan that contains @entity3649 in two different side chains (L and F), which exist in distinct molecular environments. However, little is known about the contribution of these side chains to xyloglucan function. Here, we show that @entity958 ( @entity958 ) mutants devoid of the F side chain galactosyltransferase @entity40395 ( @entity40395 ) form xyloglucan that lacks F side chains and contains much less galactosylated xylose than its wild-type counterpart. The @entity3649 -depleted xyloglucan is dysfunctional, as it leads to mutants that are dwarfed with curled rosette leaves, short petioles, and short inflorescence stems. Moreover, cell wall matrix polysaccharides, including xyloglucan and pectin, are not properly secreted and instead accumulate within intracellular aggregates. Near-normal growth is restored by generating @entity40395 mutants that produce no detectable amounts of xyloglucan. Thus, cellular processes are affected more by the presence of the dysfunctional xyloglucan than by eliminating xyloglucan altogether. To identify structural features responsible for xyloglucan dysfunction, xyloglucan structure was modified in situ by generating @entity40395 mutants that lack specific xyloglucan xylosyltransferases (XXTs) or that overexpress the XYLOGLUCAN L-SIDE CHAIN GALACTOSYLTRANSFERASE2 (XLT2) gene. Normal growth was restored in the @entity40395 -3 mutant overexpressing XLT2 and in @entity40395 -3 xxt double mutants when the dysfunctional xyloglucan was modified by doubling the amounts of galactosylated side chains. Our study assigns a role for galactosylation in normal xyloglucan function and demonstrates that altering xyloglucan side chain structure disturbs diverse cellular and physiological processes.

title: XXXX -depleted xyloglucan is dysfunctional and leads to dwarfism in @entity958 .

entities_list: @entity958 :: ('3702', 'Species') :: ['Arabidopsis thaliana', 'Arabidopsis']

entities_list: @entity3649 :: ('MESH:D005690', 'Chemical') :: ['galactose']

answer: @entity3649 :: (MESH:D005690,Chemical) :: ['Galactose']


abstract: Xyloglucan is a polysaccharide that has important roles in the formation and function of the walls that surround growing land plant cells. Many of these plants synthesize xyloglucan that contains @entity3649 in two different side chains (L and F), which exist in distinct molecular environments. However, little is known about the contribution of these side chains to xyloglucan function. Here, we show that @entity958 ( @entity958 ) mutants devoid of the F side chain galactosyltransferase @entity40395 ( @entity40395 ) form xyloglucan that lacks F side chains and contains much less galactosylated xylose than its wild-type counterpart. The @entity3649 -depleted xyloglucan is dysfunctional, as it leads to mutants that are dwarfed with curled rosette leaves, short petioles, and short inflorescence stems. Moreover, cell wall matrix polysaccharides, including xyloglucan and pectin, are not properly secreted and instead accumulate within intracellular aggregates. Near-normal growth is restored by generating @entity40395 mutants that produce no detectable amounts of xyloglucan. Thus, cellular processes are affected more by the presence of the dysfunctional xyloglucan than by eliminating xyloglucan altogether. To identify structural features responsible for xyloglucan dysfunction, xyloglucan structure was modified in situ by generating @entity40395 mutants that lack specific xyloglucan xylosyltransferases (XXTs) or that overexpress the XYLOGLUCAN L-SIDE CHAIN GALACTOSYLTRANSFERASE2 (XLT2) gene. Normal growth was restored in the @entity40395 -3 mutant overexpressing XLT2 and in @entity40395 -3 xxt double mutants when the dysfunctional xyloglucan was modified by doubling the amounts of galactosylated side chains. Our study assigns a role for galactosylation in normal xyloglucan function and demonstrates that altering xyloglucan side chain structure disturbs diverse cellular and physiological processes.

title: @entity3649 -depleted xyloglucan is dysfunctional and leads to dwarfism in XXXX .

answer: @entity958 :: (3702,Species) :: ['Arabidopsis']